Hemoglobinuria, Paroxysmal: all 192 studies
Page 2 of 2. Open to participants first (49), then studies with results posted, then the rest; newest registration first within each.
- Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood CancerCompletedNCT00975975Phase 2Results posted
- Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT00867932Phase 4Results posted
- Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
- Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic DisordersCompletedNCT00587054Phase 2Results posted
- Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological MalignanciesCompletedNCT00566696Phase 2Results posted
- Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
- Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00397813Phase 2Results posted
- Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT00122317Phase 3Results posted
- Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure SyndromesCompletedNCT00004143Phase 2Results posted
- Long-term Safety of Danicopan: IPIG Registry-based Cohort StudyActive, not recruitingNCT07413679
- Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry DataActive, not recruitingNCT07413250
- Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.Active, not recruitingNCT07212426Phase 2
- Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With AnemiaCompletedNCT07052838Phase 3
- NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical PracticeTerminatedNCT07036718
- A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy SubjectsCompletedNCT07035665Phase 1
- An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURNCompletedNCT06987864Phase 3
- Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH RegistryActive, not recruitingNCT06903234
- Study on Mass Balance of [14C]HSK39297 in Healthy Chinese Adult Male SubjectsCompletedNCT06852092Phase 1
- Phase Ib Clinical Study to Evaluate the Safety and Tolerability of VSA012 Injection in Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingNCT06848296Phase 1
- A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria PatientsActive, not recruitingNCT06764303Phase 2
- Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody TreatmentCompletedNCT06715943Phase 3
- Real-life Treatment Outcomes of Ravulizumab in PNHActive, not recruitingNCT06633536
- Specified Drug-use Surveillance of Fabhalta CapsulesActive, not recruitingNCT06606314
- A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyCompletedNCT06593938Phase 3
- A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）CompletedNCT06561841Phase 2
- A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy AdultsCompletedNCT06326814Phase 1
- Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingNCT06298955Phase 2
- A Study of Single and Multiple Doses of LP-005 in Healthy Adult ParticipantsCompletedNCT06294301Phase 1
- Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingNCT06238544Phase 2
- A Real-world, Multi-center, Prospective, Observational Study for PNH in ChinaCompletedNCT06154512
- Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT06100900Phase 1
- Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT06051357Phase 2
- A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT06050226Phase 2
- Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal HemoglobinuriaNo longer availableNCT06028594
- Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to RavulizumabCompletedNCT05972967Phase 2
- Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT05889299Phase 1
- Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve PatientsCompletedNCT05842486
- Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult SubjectsCompletedNCT05828485Phase 1
- A Study of Multiple Ascending Doses MY008211A in Healthy AdultsCompletedNCT05828472Phase 1
- A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Active, not recruitingNCT05776472
- A Study of Single-dose MY008211A in Healthy AdultsCompletedNCT05642585Phase 1
- To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104CompletedNCT05490017Phase 1
- To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104Active, not recruitingNCT05476887Phase 2
- A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNHActive, not recruitingNCT05389449Phase 3
- Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT05274633
- A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentActive, not recruitingNCT05133531Phase 3
- Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in ChinaCompletedNCT05125341
- Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)CompletedNCT04965597Phase 2
- Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingNCT04747613Phase 3
- A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)CompletedNCT04679103Phase 3
- Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®CompletedNCT04671810
- Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNHCompletedNCT04463056Phase 3
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement InhibitorsActive, not recruitingNCT04432584Phase 3
- First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNHCompletedNCT04330534Phase 1/2
- Electronic Patient-reported Outcome Monitoring in Aplastic Anemia and Paroxysmal Nocturnal HemoglobinuriaCompletedNCT04128943
- The Pharmacokinetics and Pharmacodynamics of Eculizumab in Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT04079257
- Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT04060264Phase 3
- Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNHStatus unknownNCT03866681Phase 4
- Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576CompletedNCT03588026Phase 3
- Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUSActive, not recruitingNCT03329365
- Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT03157635Phase 1/2
- Unrelated And Partially Matched Related Donor PSCT w/ T Cell Receptor (TCR) αβ Depletion for Patients With BMFActive, not recruitingNCT03047746Not applicable
- Hematopoietic Stem Cell Transplant for High Risk HemoglobinopathiesTerminatedNCT02179359Not applicable
- Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)Status unknownNCT01760096Phase 2
- Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal HemoglobinuriaStatus unknownNCT01642979Phase 2
- Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies StudyCompletedNCT01412047
- Paroxysmal Nocturnal Hemoglobinuria (PNH) RegistryCompletedNCT01374360
- Unrelated Donor Stem Cell TransplantationCompletedNCT01364363Not applicable
- Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)TerminatedNCT01335165Phase 1
- Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell DiseaseCompletedNCT01294891
- Nonmyeloablative Allogeneic TransplantCompletedNCT01272817Not applicable
- Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) PatientsStatus unknownNCT01224483
- Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure SyndromesCompletedNCT01192425
- Study of Global Coagulation Tests in Patients With Paroxysmal Nocturnal HaemoglobinuriaCompletedNCT01020188
- Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCTCompletedNCT00774527Phase 3
- Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure SyndromeCompletedNCT00731328Phase 2
- The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT00721864
- Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related DonorsCompletedNCT00618969Phase 2
- The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment ProtocolApproved for marketingNCT00438789
- Identifying Characteristics of Bone Marrow Failure SyndromesStatus unknownNCT00315419
- Haploidentical Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00186823Phase 3
- Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00152139Phase 3
- Haploidentical Stem Cell Transplant for Treatment Refractory Hematological MalignanciesCompletedNCT00145613Phase 2
- Stem Cell Transplantation as Immunotherapy for Hematologic MalignanciesCompletedNCT00143559Phase 2
- Eculizumab to Treat Paroxysmal Nocturnal HemoglobinuriaCompletedNCT00130000Phase 3
- Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) PatientsCompletedNCT00122330Phase 3
- Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With EculizumabCompletedNCT00122304Phase 3
- Eculizumab in Treating Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT00112983Phase 3
- Eculizumab to Treat Paroxysmal Nocturnal HemoglobinuriaCompletedNCT00098280Phase 3
- Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT00039923
- Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
- Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal HemoglobinuriaCompletedNCT00004464Phase 2